565. Antimicrobial susceptibility profiles of Acinetobacter species in blood: 10-year experience from a major United States reference laboratory Article Swipe
Bismarck S Bisono Garcia
,
Nischal Ranganath
,
Nicholas Streck
,
Audrey N. Schuetz
,
Aditya Shah
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofad500.634
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofad500.634
Background Antimicrobial resistance (AMR) is a threat to healthcare, and infections with antimicrobial resistant organisms carry significant morbidity and mortality. Owing to high rates of AMR, the Centers for Disease Control and Prevention listed Acinetobacter baumannii as a top priority pathogen for research and development of new antimicrobial agents. Antimicrobial susceptibility testing is challenging for this organism, and susceptibility profiles are variable, leading to need of a potential guidance document with assistance in selecting effective empiric therapeutic regimens. Methods We retrospectively reviewed the microbiology and antimicrobial susceptibility testing (AST) results for Acinetobacter spp. from blood culture isolates submitted to Mayo Clinic Laboratories from December 2012 to 2022. AST was performed using agar dilution and interpretations following Clinical & Laboratory Standards Institute (CLSI) guidelines. Isolates were identified by MALDI mass spectrometry and/or 16S sequencing, as available (Figure 1).Figure 1:Isolate identification Isolate identification description. Isolates were analyzed based on this classification used in out laboratory. Results 804 blood culture isolates were included. A. baumannii/calcoaceticus complex (27%) was most frequently isolated, followed by A. lwoffii (22%), and showed the highest resistance across all antimicrobials (73% susceptible or below) (Figure 2). A. baumannii/calcoaceticus complex showed rising resistance rates over time from 2012 to 2022 for meropenem, minocycline and ampicillin-sulbactam (Figure 3). Cefiderocol non-susceptible rate was 35% for A. baumannii/calcoaceticus complex.Figure 2:Antimicrobial susceptibility profiles for Acinetobacter spp. Description of susceptibility profiles for Acinetobacter spp. isolates, based on the classification used by our laboratory. Antimicrobials are presented at the top and isolates on the left. Number of isolates analyzed are presented in the table with the percentage of the isolates susceptible to each antibiotic class in parenthesis.Figure 3:Acinetobacter baumannii/calcoaceticus complex isolates and resistance, trend Trend of isolates per year and resistance percentage to meropenem, colistin, minocycline and amp-sulb. Number of isolates per year at the base of each bar; percentage of resistance for antimicrobials expressed on lines. Amp-sulb = ampicillin-sulbactam. Conclusion A. baumannii/calcoaceticus complex showed high levels of resistance ( >75%) across multiple antimicrobials and increasing rates of resistance over time from 2012 to 2022. A high number of cefiderocol non-susceptible organisms is also concerning (Figure 2). Disclosures Audrey N. Schuetz, MD, Merck: Advisor/Consultant
Related Topics
Concepts
Acinetobacter baumannii
Antimicrobial
Acinetobacter calcoaceticus
Microbiology
Acinetobacter
Medicine
Clinical microbiology
Sulbactam
Antibiotic resistance
Agar dilution
Blood culture
Meropenem
Drug resistance
Ampicillin
Antibiotics
Biology
Minimum inhibitory concentration
Imipenem
Bacteria
Pseudomonas aeruginosa
Genetics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ofid/ofad500.634
- https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.634/53771795/ofad500.634.pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4389031139
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4389031139Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ofid/ofad500.634Digital Object Identifier
- Title
-
565. Antimicrobial susceptibility profiles of Acinetobacter species in blood: 10-year experience from a major United States reference laboratoryWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-11-27Full publication date if available
- Authors
-
Bismarck S Bisono Garcia, Nischal Ranganath, Nicholas Streck, Audrey N. Schuetz, Aditya ShahList of authors in order
- Landing page
-
https://doi.org/10.1093/ofid/ofad500.634Publisher landing page
- PDF URL
-
https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.634/53771795/ofad500.634.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.634/53771795/ofad500.634.pdfDirect OA link when available
- Concepts
-
Acinetobacter baumannii, Antimicrobial, Acinetobacter calcoaceticus, Microbiology, Acinetobacter, Medicine, Clinical microbiology, Sulbactam, Antibiotic resistance, Agar dilution, Blood culture, Meropenem, Drug resistance, Ampicillin, Antibiotics, Biology, Minimum inhibitory concentration, Imipenem, Bacteria, Pseudomonas aeruginosa, GeneticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4389031139 |
|---|---|
| doi | https://doi.org/10.1093/ofid/ofad500.634 |
| ids.doi | https://doi.org/10.1093/ofid/ofad500.634 |
| ids.openalex | https://openalex.org/W4389031139 |
| fwci | 0.0 |
| type | article |
| title | 565. Antimicrobial susceptibility profiles of Acinetobacter species in blood: 10-year experience from a major United States reference laboratory |
| biblio.issue | Supplement_2 |
| biblio.volume | 10 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10147 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1313 |
| topics[0].subfield.display_name | Molecular Medicine |
| topics[0].display_name | Antibiotic Resistance in Bacteria |
| topics[1].id | https://openalex.org/T10897 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9900000095367432 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2402 |
| topics[1].subfield.display_name | Applied Microbiology and Biotechnology |
| topics[1].display_name | Antibiotic Use and Resistance |
| topics[2].id | https://openalex.org/T12167 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9865999817848206 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1308 |
| topics[2].subfield.display_name | Clinical Biochemistry |
| topics[2].display_name | Bacterial Identification and Susceptibility Testing |
| is_xpac | False |
| apc_list.value | 3064 |
| apc_list.currency | USD |
| apc_list.value_usd | 3064 |
| apc_paid.value | 3064 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3064 |
| concepts[0].id | https://openalex.org/C2776315533 |
| concepts[0].level | 4 |
| concepts[0].score | 0.7831777334213257 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q3241189 |
| concepts[0].display_name | Acinetobacter baumannii |
| concepts[1].id | https://openalex.org/C4937899 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6621793508529663 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q68541106 |
| concepts[1].display_name | Antimicrobial |
| concepts[2].id | https://openalex.org/C2775859738 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6320029497146606 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q4674168 |
| concepts[2].display_name | Acinetobacter calcoaceticus |
| concepts[3].id | https://openalex.org/C89423630 |
| concepts[3].level | 1 |
| concepts[3].score | 0.617567777633667 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[3].display_name | Microbiology |
| concepts[4].id | https://openalex.org/C2778523567 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6055728793144226 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q310457 |
| concepts[4].display_name | Acinetobacter |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.5756306648254395 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C2992965680 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5226035714149475 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q598976 |
| concepts[6].display_name | Clinical microbiology |
| concepts[7].id | https://openalex.org/C2778478555 |
| concepts[7].level | 5 |
| concepts[7].score | 0.5166802406311035 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q423393 |
| concepts[7].display_name | Sulbactam |
| concepts[8].id | https://openalex.org/C94665300 |
| concepts[8].level | 3 |
| concepts[8].score | 0.5128265023231506 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q63391344 |
| concepts[8].display_name | Antibiotic resistance |
| concepts[9].id | https://openalex.org/C2780493024 |
| concepts[9].level | 4 |
| concepts[9].score | 0.5053496956825256 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q19903202 |
| concepts[9].display_name | Agar dilution |
| concepts[10].id | https://openalex.org/C2779473907 |
| concepts[10].level | 3 |
| concepts[10].score | 0.4695701599121094 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q886695 |
| concepts[10].display_name | Blood culture |
| concepts[11].id | https://openalex.org/C2779375183 |
| concepts[11].level | 4 |
| concepts[11].score | 0.415073424577713 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q421670 |
| concepts[11].display_name | Meropenem |
| concepts[12].id | https://openalex.org/C114851261 |
| concepts[12].level | 2 |
| concepts[12].score | 0.41481178998947144 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q12147416 |
| concepts[12].display_name | Drug resistance |
| concepts[13].id | https://openalex.org/C2776021129 |
| concepts[13].level | 3 |
| concepts[13].score | 0.41381973028182983 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q244150 |
| concepts[13].display_name | Ampicillin |
| concepts[14].id | https://openalex.org/C501593827 |
| concepts[14].level | 2 |
| concepts[14].score | 0.3048666715621948 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[14].display_name | Antibiotics |
| concepts[15].id | https://openalex.org/C86803240 |
| concepts[15].level | 0 |
| concepts[15].score | 0.3037886917591095 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[15].display_name | Biology |
| concepts[16].id | https://openalex.org/C176947019 |
| concepts[16].level | 3 |
| concepts[16].score | 0.19415569305419922 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q597889 |
| concepts[16].display_name | Minimum inhibitory concentration |
| concepts[17].id | https://openalex.org/C2779631663 |
| concepts[17].level | 4 |
| concepts[17].score | 0.15936630964279175 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q425152 |
| concepts[17].display_name | Imipenem |
| concepts[18].id | https://openalex.org/C523546767 |
| concepts[18].level | 2 |
| concepts[18].score | 0.1261538565158844 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q10876 |
| concepts[18].display_name | Bacteria |
| concepts[19].id | https://openalex.org/C2777637488 |
| concepts[19].level | 3 |
| concepts[19].score | 0.12082573771476746 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q31856 |
| concepts[19].display_name | Pseudomonas aeruginosa |
| concepts[20].id | https://openalex.org/C54355233 |
| concepts[20].level | 1 |
| concepts[20].score | 0.053411006927490234 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[20].display_name | Genetics |
| keywords[0].id | https://openalex.org/keywords/acinetobacter-baumannii |
| keywords[0].score | 0.7831777334213257 |
| keywords[0].display_name | Acinetobacter baumannii |
| keywords[1].id | https://openalex.org/keywords/antimicrobial |
| keywords[1].score | 0.6621793508529663 |
| keywords[1].display_name | Antimicrobial |
| keywords[2].id | https://openalex.org/keywords/acinetobacter-calcoaceticus |
| keywords[2].score | 0.6320029497146606 |
| keywords[2].display_name | Acinetobacter calcoaceticus |
| keywords[3].id | https://openalex.org/keywords/microbiology |
| keywords[3].score | 0.617567777633667 |
| keywords[3].display_name | Microbiology |
| keywords[4].id | https://openalex.org/keywords/acinetobacter |
| keywords[4].score | 0.6055728793144226 |
| keywords[4].display_name | Acinetobacter |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.5756306648254395 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/clinical-microbiology |
| keywords[6].score | 0.5226035714149475 |
| keywords[6].display_name | Clinical microbiology |
| keywords[7].id | https://openalex.org/keywords/sulbactam |
| keywords[7].score | 0.5166802406311035 |
| keywords[7].display_name | Sulbactam |
| keywords[8].id | https://openalex.org/keywords/antibiotic-resistance |
| keywords[8].score | 0.5128265023231506 |
| keywords[8].display_name | Antibiotic resistance |
| keywords[9].id | https://openalex.org/keywords/agar-dilution |
| keywords[9].score | 0.5053496956825256 |
| keywords[9].display_name | Agar dilution |
| keywords[10].id | https://openalex.org/keywords/blood-culture |
| keywords[10].score | 0.4695701599121094 |
| keywords[10].display_name | Blood culture |
| keywords[11].id | https://openalex.org/keywords/meropenem |
| keywords[11].score | 0.415073424577713 |
| keywords[11].display_name | Meropenem |
| keywords[12].id | https://openalex.org/keywords/drug-resistance |
| keywords[12].score | 0.41481178998947144 |
| keywords[12].display_name | Drug resistance |
| keywords[13].id | https://openalex.org/keywords/ampicillin |
| keywords[13].score | 0.41381973028182983 |
| keywords[13].display_name | Ampicillin |
| keywords[14].id | https://openalex.org/keywords/antibiotics |
| keywords[14].score | 0.3048666715621948 |
| keywords[14].display_name | Antibiotics |
| keywords[15].id | https://openalex.org/keywords/biology |
| keywords[15].score | 0.3037886917591095 |
| keywords[15].display_name | Biology |
| keywords[16].id | https://openalex.org/keywords/minimum-inhibitory-concentration |
| keywords[16].score | 0.19415569305419922 |
| keywords[16].display_name | Minimum inhibitory concentration |
| keywords[17].id | https://openalex.org/keywords/imipenem |
| keywords[17].score | 0.15936630964279175 |
| keywords[17].display_name | Imipenem |
| keywords[18].id | https://openalex.org/keywords/bacteria |
| keywords[18].score | 0.1261538565158844 |
| keywords[18].display_name | Bacteria |
| keywords[19].id | https://openalex.org/keywords/pseudomonas-aeruginosa |
| keywords[19].score | 0.12082573771476746 |
| keywords[19].display_name | Pseudomonas aeruginosa |
| keywords[20].id | https://openalex.org/keywords/genetics |
| keywords[20].score | 0.053411006927490234 |
| keywords[20].display_name | Genetics |
| language | en |
| locations[0].id | doi:10.1093/ofid/ofad500.634 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735126445 |
| locations[0].source.issn | 2328-8957 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2328-8957 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Open Forum Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.634/53771795/ofad500.634.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Open Forum Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/ofid/ofad500.634 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:10678832 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | cc-by |
| locations[1].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10678832/pdf/ofad500.634.pdf |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/cc-by |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Open Forum Infect Dis |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10678832 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5104203482 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Bismarck S Bisono Garcia |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[0].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[0].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[0].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Mayo Clinic |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Bismarck S Bisono Garcia |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[1].author.id | https://openalex.org/A5049492804 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-9538-6214 |
| authorships[1].author.display_name | Nischal Ranganath |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[1].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[1].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[1].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Mayo Clinic |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Nischal Ranganath |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[2].author.id | https://openalex.org/A5017312580 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6704-3406 |
| authorships[2].author.display_name | Nicholas Streck |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[2].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[2].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[2].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Mayo Clinic |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Nicholas Streck |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[3].author.id | https://openalex.org/A5090823218 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5837-270X |
| authorships[3].author.display_name | Audrey N. Schuetz |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[3].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[3].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[3].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Mayo Clinic |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Audrey N Schuetz |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| authorships[4].author.id | https://openalex.org/A5012809798 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-2023-394X |
| authorships[4].author.display_name | Aditya Shah |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[4].affiliations[0].raw_affiliation_string | Mayo Clinic , Rochester, Minnesota |
| authorships[4].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[4].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Mayo Clinic |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Aditya Shah |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Mayo Clinic , Rochester, Minnesota |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.634/53771795/ofad500.634.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 565. Antimicrobial susceptibility profiles of Acinetobacter species in blood: 10-year experience from a major United States reference laboratory |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10147 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1313 |
| primary_topic.subfield.display_name | Molecular Medicine |
| primary_topic.display_name | Antibiotic Resistance in Bacteria |
| related_works | https://openalex.org/W2607545819, https://openalex.org/W1990062545, https://openalex.org/W2053289745, https://openalex.org/W1983619272, https://openalex.org/W2146740860, https://openalex.org/W2076749358, https://openalex.org/W3030376127, https://openalex.org/W2412817691, https://openalex.org/W3154072884, https://openalex.org/W2890092200 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/ofid/ofad500.634 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735126445 |
| best_oa_location.source.issn | 2328-8957 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2328-8957 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Open Forum Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.634/53771795/ofad500.634.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Open Forum Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ofid/ofad500.634 |
| primary_location.id | doi:10.1093/ofid/ofad500.634 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735126445 |
| primary_location.source.issn | 2328-8957 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2328-8957 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Open Forum Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.634/53771795/ofad500.634.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Open Forum Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/ofid/ofad500.634 |
| publication_date | 2023-11-27 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.( | 324 |
| abstract_inverted_index.= | 313 |
| abstract_inverted_index.A | 340 |
| abstract_inverted_index.a | 6, 38, 67 |
| abstract_inverted_index.A. | 161, 171, 188, 214, 316 |
| abstract_inverted_index.N. | 354 |
| abstract_inverted_index.We | 80 |
| abstract_inverted_index.as | 37, 134 |
| abstract_inverted_index.at | 242, 298 |
| abstract_inverted_index.by | 127, 170, 236 |
| abstract_inverted_index.in | 73, 151, 256, 270 |
| abstract_inverted_index.is | 5, 53, 347 |
| abstract_inverted_index.of | 25, 46, 66, 224, 251, 262, 280, 294, 301, 305, 322, 332, 343 |
| abstract_inverted_index.on | 147, 232, 247, 310 |
| abstract_inverted_index.or | 184 |
| abstract_inverted_index.to | 8, 22, 64, 99, 106, 199, 266, 287, 338 |
| abstract_inverted_index.16S | 132 |
| abstract_inverted_index.2). | 187, 351 |
| abstract_inverted_index.3). | 207 |
| abstract_inverted_index.35% | 212 |
| abstract_inverted_index.804 | 155 |
| abstract_inverted_index.AST | 108 |
| abstract_inverted_index.MD, | 356 |
| abstract_inverted_index.all | 180 |
| abstract_inverted_index.and | 10, 19, 32, 44, 58, 85, 114, 174, 204, 245, 276, 284, 291, 329 |
| abstract_inverted_index.are | 61, 240, 254 |
| abstract_inverted_index.for | 29, 42, 55, 91, 201, 213, 220, 227, 307 |
| abstract_inverted_index.new | 47 |
| abstract_inverted_index.our | 237 |
| abstract_inverted_index.out | 152 |
| abstract_inverted_index.per | 282, 296 |
| abstract_inverted_index.the | 27, 83, 176, 233, 243, 248, 257, 260, 263, 299 |
| abstract_inverted_index.top | 39, 244 |
| abstract_inverted_index.was | 109, 165, 211 |
| abstract_inverted_index.(73% | 182 |
| abstract_inverted_index.2012 | 105, 198, 337 |
| abstract_inverted_index.2022 | 200 |
| abstract_inverted_index.AMR, | 26 |
| abstract_inverted_index.Mayo | 100 |
| abstract_inverted_index.agar | 112 |
| abstract_inverted_index.also | 348 |
| abstract_inverted_index.bar; | 303 |
| abstract_inverted_index.base | 300 |
| abstract_inverted_index.each | 267, 302 |
| abstract_inverted_index.from | 94, 103, 197, 336 |
| abstract_inverted_index.high | 23, 320, 341 |
| abstract_inverted_index.mass | 129 |
| abstract_inverted_index.most | 166 |
| abstract_inverted_index.need | 65 |
| abstract_inverted_index.over | 195, 334 |
| abstract_inverted_index.rate | 210 |
| abstract_inverted_index.spp. | 93, 222, 229 |
| abstract_inverted_index.this | 56, 148 |
| abstract_inverted_index.time | 196, 335 |
| abstract_inverted_index.used | 150, 235 |
| abstract_inverted_index.were | 125, 144, 159 |
| abstract_inverted_index.with | 12, 71, 259 |
| abstract_inverted_index.year | 283, 297 |
| abstract_inverted_index.& | 118 |
| abstract_inverted_index.(27%) | 164 |
| abstract_inverted_index.(AMR) | 4 |
| abstract_inverted_index.(AST) | 89 |
| abstract_inverted_index.2022. | 107, 339 |
| abstract_inverted_index.MALDI | 128 |
| abstract_inverted_index.Owing | 21 |
| abstract_inverted_index.Trend | 279 |
| abstract_inverted_index.based | 146, 231 |
| abstract_inverted_index.blood | 95, 156 |
| abstract_inverted_index.carry | 16 |
| abstract_inverted_index.class | 269 |
| abstract_inverted_index.left. | 249 |
| abstract_inverted_index.rates | 24, 194, 331 |
| abstract_inverted_index.table | 258 |
| abstract_inverted_index.trend | 278 |
| abstract_inverted_index.using | 111 |
| abstract_inverted_index.(22%), | 173 |
| abstract_inverted_index.(CLSI) | 122 |
| abstract_inverted_index.Audrey | 353 |
| abstract_inverted_index.Clinic | 101 |
| abstract_inverted_index.Merck: | 357 |
| abstract_inverted_index.Number | 250, 293 |
| abstract_inverted_index.across | 179, 326 |
| abstract_inverted_index.and/or | 131 |
| abstract_inverted_index.below) | 185 |
| abstract_inverted_index.levels | 321 |
| abstract_inverted_index.lines. | 311 |
| abstract_inverted_index.listed | 34 |
| abstract_inverted_index.number | 342 |
| abstract_inverted_index.rising | 192 |
| abstract_inverted_index.showed | 175, 191, 319 |
| abstract_inverted_index.threat | 7 |
| abstract_inverted_index.(Figure | 136, 186, 206, 350 |
| abstract_inverted_index.Centers | 28 |
| abstract_inverted_index.Control | 31 |
| abstract_inverted_index.Disease | 30 |
| abstract_inverted_index.Isolate | 140 |
| abstract_inverted_index.Methods | 79 |
| abstract_inverted_index.Results | 154 |
| abstract_inverted_index.agents. | 49 |
| abstract_inverted_index.complex | 163, 190, 274, 318 |
| abstract_inverted_index.culture | 96, 157 |
| abstract_inverted_index.empiric | 76 |
| abstract_inverted_index.highest | 177 |
| abstract_inverted_index.leading | 63 |
| abstract_inverted_index.lwoffii | 172 |
| abstract_inverted_index.results | 90 |
| abstract_inverted_index.testing | 52, 88 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Amp-sulb | 312 |
| abstract_inverted_index.Clinical | 117 |
| abstract_inverted_index.December | 104 |
| abstract_inverted_index.Isolates | 124, 143 |
| abstract_inverted_index.Schuetz, | 355 |
| abstract_inverted_index.analyzed | 145, 253 |
| abstract_inverted_index.dilution | 113 |
| abstract_inverted_index.document | 70 |
| abstract_inverted_index.followed | 169 |
| abstract_inverted_index.guidance | 69 |
| abstract_inverted_index.isolates | 97, 158, 246, 252, 264, 275, 281, 295 |
| abstract_inverted_index.multiple | 327 |
| abstract_inverted_index.pathogen | 41 |
| abstract_inverted_index.priority | 40 |
| abstract_inverted_index.profiles | 60, 219, 226 |
| abstract_inverted_index.research | 43 |
| abstract_inverted_index.reviewed | 82 |
| abstract_inverted_index.1).Figure | 137 |
| abstract_inverted_index.1:Isolate | 138 |
| abstract_inverted_index.Institute | 121 |
| abstract_inverted_index.Standards | 120 |
| abstract_inverted_index.amp-sulb. | 292 |
| abstract_inverted_index.available | 135 |
| abstract_inverted_index.baumannii | 36 |
| abstract_inverted_index.colistin, | 289 |
| abstract_inverted_index.effective | 75 |
| abstract_inverted_index.expressed | 309 |
| abstract_inverted_index.following | 116 |
| abstract_inverted_index.included. | 160 |
| abstract_inverted_index.isolated, | 168 |
| abstract_inverted_index.isolates, | 230 |
| abstract_inverted_index.morbidity | 18 |
| abstract_inverted_index.organism, | 57 |
| abstract_inverted_index.organisms | 15, 346 |
| abstract_inverted_index.performed | 110 |
| abstract_inverted_index.potential | 68 |
| abstract_inverted_index.presented | 241, 255 |
| abstract_inverted_index.regimens. | 78 |
| abstract_inverted_index.resistant | 14 |
| abstract_inverted_index.selecting | 74 |
| abstract_inverted_index.submitted | 98 |
| abstract_inverted_index.variable, | 62 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 315 |
| abstract_inverted_index.Laboratory | 119 |
| abstract_inverted_index.Prevention | 33 |
| abstract_inverted_index.antibiotic | 268 |
| abstract_inverted_index.assistance | 72 |
| abstract_inverted_index.concerning | 349 |
| abstract_inverted_index.frequently | 167 |
| abstract_inverted_index.identified | 126 |
| abstract_inverted_index.increasing | 330 |
| abstract_inverted_index.infections | 11 |
| abstract_inverted_index.meropenem, | 202, 288 |
| abstract_inverted_index.mortality. | 20 |
| abstract_inverted_index.percentage | 261, 286, 304 |
| abstract_inverted_index.resistance | 3, 178, 193, 285, 306, 323, 333 |
| abstract_inverted_index.Cefiderocol | 208 |
| abstract_inverted_index.Description | 223 |
| abstract_inverted_index.Disclosures | 352 |
| abstract_inverted_index.cefiderocol | 344 |
| abstract_inverted_index.challenging | 54 |
| abstract_inverted_index.development | 45 |
| abstract_inverted_index.guidelines. | 123 |
| abstract_inverted_index.healthcare, | 9 |
| abstract_inverted_index.laboratory. | 153, 238 |
| abstract_inverted_index.minocycline | 203, 290 |
| abstract_inverted_index.resistance, | 277 |
| abstract_inverted_index.sequencing, | 133 |
| abstract_inverted_index.significant | 17 |
| abstract_inverted_index.susceptible | 183, 265 |
| abstract_inverted_index.therapeutic | 77 |
| abstract_inverted_index.>75%) | 325 |
| abstract_inverted_index.Laboratories | 102 |
| abstract_inverted_index.description. | 142 |
| abstract_inverted_index.microbiology | 84 |
| abstract_inverted_index.spectrometry | 130 |
| abstract_inverted_index.Acinetobacter | 35, 92, 221, 228 |
| abstract_inverted_index.Antimicrobial | 2, 50 |
| abstract_inverted_index.antimicrobial | 13, 48, 86 |
| abstract_inverted_index.Antimicrobials | 239 |
| abstract_inverted_index.antimicrobials | 181, 308, 328 |
| abstract_inverted_index.classification | 149, 234 |
| abstract_inverted_index.complex.Figure | 216 |
| abstract_inverted_index.identification | 139, 141 |
| abstract_inverted_index.susceptibility | 51, 59, 87, 218, 225 |
| abstract_inverted_index.2:Antimicrobial | 217 |
| abstract_inverted_index.3:Acinetobacter | 272 |
| abstract_inverted_index.interpretations | 115 |
| abstract_inverted_index.non-susceptible | 209, 345 |
| abstract_inverted_index.retrospectively | 81 |
| abstract_inverted_index.Advisor/Consultant | 358 |
| abstract_inverted_index.parenthesis.Figure | 271 |
| abstract_inverted_index.ampicillin-sulbactam | 205 |
| abstract_inverted_index.ampicillin-sulbactam. | 314 |
| abstract_inverted_index.baumannii/calcoaceticus | 162, 189, 215, 273, 317 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.14727453 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |